ALMR Alamar Biosciences, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 2104204 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets19.7%
Debt / equity0.00x
Current ratio9.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $33.55M | $29.43M | $26.04M | $19.91M | $16.16M | $13.09M |
| Cost of revenue | $12.90M | $11.71M | $11.58M | $8.02M | $7.58M | $6.70M |
| Gross profit | $20.64M | $17.72M | $14.46M | $11.90M | $8.58M | $6.39M |
| R&D expense | $16.17M | $13.82M | $13.02M | $10.21M | $8.89M | $8.30M |
| SG&A expense | $19.62M | $17.43M | $13.79M | $9.58M | $7.61M | $6.64M |
| Operating income | -$15.14M | -$13.53M | -$12.35M | -$7.88M | -$7.92M | -$8.55M |
| Pretax income | -$13.25M | -$13.29M | -$20.86M | -$7.56M | -$7.02M | -$7.66M |
| Income tax | $94,000 | -$93,000 | $464,000 | $440,000 | — | — |
| Net income | -$13.34M | -$13.20M | -$21.32M | -$8.00M | -$7.02M | -$7.66M |
| EBITDA | -$13.71M | -$12.40M | -$11.18M | -$6.90M | -$7.00M | -$7.67M |
| EPS (basic) | -0.19 | -0.22 | -1.74 | -0.69 | -0.62 | -0.68 |
| EPS (diluted) | -0.19 | -0.22 | -1.74 | -0.69 | -0.62 | -0.68 |
| Weighted avg. shares (diluted) | 69.11M | 58.67M | 12.26M | 11.60M | 11.41M | 11.26M |
| Balance sheet | ||||||
| Cash & equivalents | $121.53M | $132.97M | $64.59M | $47.64M | — | — |
| Short-term investments | $105.05M | $117.08M | $0 | — | — | — |
| Receivables | $21.61M | $20.34M | $19.52M | — | — | — |
| Inventory | $54.13M | $45.41M | $39.93M | — | — | — |
| Current assets | $317.69M | $331.38M | $141.47M | — | — | — |
| PP&E, net | $15.24M | $13.36M | $10.47M | — | — | — |
| Total assets | $378.03M | $390.98M | $186.45M | — | — | — |
| Current liabilities | $33.48M | $27.96M | $24.05M | — | — | — |
| Total liabilities | $74.32M | $78.12M | $129.53M | — | — | — |
| Shareholders' equity | $303.70M | $312.86M | -$178.07M | -$153.34M | -$146.61M | -$140.29M |
| Cash flow statement | ||||||
| Operating cash flow | -$14.73M | -$11.32M | -$20.35M | -$14.14M | -$11.88M | -$13.07M |
| Capital expenditure | $463,000 | $3.64M | $600,000 | $1.22M | $753,000 | $554,000 |
| Free cash flow | -$15.20M | -$14.96M | -$20.95M | -$15.36M | -$12.63M | -$13.62M |
| Investing cash flow | $11.74M | -$120.80M | -$778,000 | $14.19M | $17.95M | $17.02M |
| Financing cash flow | -$9.85M | $201.84M | $55.76M | $10.40M | $164,000 | $243,000 |
| Depreciation & amortization | $1.42M | $1.13M | $1.17M | $983,000 | $919,000 | $888,000 |
| Stock-based compensation | $3.92M | $3.28M | $1.47M | $705,000 | $680,000 | $619,000 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.